At a Glance
- Company: Neurocrine Biosciences; Soleno Therapeutics (NASDAQ: SLNO)
- Location: San Diego (Neurocrine); US-based (Soleno)
- Deal value: $2.9B all-cash ($53/share, 34% premium)
- Focus area: Vykat XR (diazoxide choline) for Prader-Willi hyperphagia
- Next steps: Close in 3 months; US launch expansion, EU filings
What happened?
Neurocrine Biosciences announced on 6 April 2026 it would acquire Soleno Therapeutics for $2.9 billion in cash, paying $53 per share—a 34% premium to Soleno’s 2 April close. The deal gives Neurocrine Vykat XR, the only FDA-approved treatment for hyperphagia (insatiable hunger) in Prader-Willi syndrome (PWS), approved in March 2025 with $190M in 2025 sales ($92M Q4).
Why does it matter?
PWS hyperphagia affects ~15,000 US patients, driving life-threatening obesity; Vykat XR targets the root cause, with exclusivity to mid-2040s and blockbuster potential (~$1B+ peak sales). Neurocrine’s first major M&A diversifies beyond CNS into rare metabolic disease, accretive to 2026 revenue.
Who’s behind it?
Neurocrine (CNS leader, e.g., Ingrezza) enters rare metabolic via Soleno’s Vykat XR, which prevents weight gain and food-seeking behaviours. Soleno launched post-FDA nod, treating ~1,250 patients.
How was it achieved?
Vykat XR (extended-release diazoxide choline) reduces hyperphagia via hypothalamic KATP channel modulation; 4.5+ years of safety data supported approval. Neurocrine funds with cash/debt; no financing condition.
What’s next?
Close within 3 months pending approvals; Neurocrine expands US sales (~10,000 eligible patients), eyes Europe. Integrates with crenessity (CAH); optimises capital post-close.
What are people saying?
Neurocrine CFO Matt Abernethy: “Exceptional strategic/financial fit… blockbuster potential.” CMO Sanjay Keswani: “Transformative for patients independent of weight.”